BMC’s Yawkey building doors are now closed as an entrance as part of our ongoing efforts to enhance our campus and provide you with the best clinical care.

All patients and visitors on our main campus must enter our hospital via Shapiro, Menino, or Moakley buildings, where they will be greeted by team members at a new centralized check-in desk before continuing to the hospital. We are excited to welcome you and appreciate your patience as we improve our facilities.


Umit Tapan, MD, is a thoracic oncologist at Boston Medical Center (BMC) and an assistant professor of Medicine at Boston University Chobanian & Avedisian School of Medicine. Dr. Tapan specializes in non-small cell lung cancer, small cell lung cancer, mesothelioma, immunotherapy, targeted therapy/precision medicine. His research interests center on reducing disparities in lung cancer treatment, improving access to new treatments such as immunotherapy and targeted treatment. After receiving his medical degree from Hacettepe University School of Medicine in Turkey, Dr. Tapan completed his internship and residency at Steward Carney Hospital and a fellowship in hematology and oncology at Boston University Medical Center.

  • Departments

  • Specialties

    Non-small cell lung cancer, small-cell lung cancer, mesothelioma, immunotherapy, targeted therapy

  • Languages

  • Administrative Title

    Assistant Professor of Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine. Member, BU-BMC Cancer Center. Member, Evans Center for Interdisciplinary Biomedical Research, Boston University.

  • Residency

    Internal Medicine, Steward Carney Hospital, 2010-2012
  • Fellowship

    Hematology and Medical Oncology, Boston University Medical Center, 2014-2015
  • Education

    Hacettepe University Faculty of Medicine, Turkey, 2006
  • Board Certifications

    Internal Medicine, Hematology, Medical Oncology, American Board of Internal Medicine
  • Research Interests

    Disparities in lung cancer care, predictors of immunotherapy response/toxicity